Ovarian Cancer - Pipeline Review, H2 2017

  • ID: 4446848
  • Report
  • 2232 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • 3-V Biosciences Inc
  • Bionomics Ltd
  • F. Hoffmann-La Roche Ltd
  • Kyowa Hakko Kirin Co Ltd
  • Oncobiologics Inc
  • Sanofi Pasteur SA
  • MORE
Ovarian Cancer - Pipeline Review, H2 2017

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Ovarian Cancer - Pipeline Review, H2 2017, provides an overview of the Ovarian Cancer (Oncology) pipeline landscape.

Ovarian cancer is any cancerous growth that may occur in different parts of the ovary. The majority of ovarian cancers arise from the epithelium (outer lining) of the ovary. Signs and symptoms of ovarian cancer include pelvic discomfort or pain, indigestion, gas or nausea, changes in bowel habits, such as constipation, loss of appetite and low back pain. The predisposing factors include age and family history. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

The latest Pharmaceutical and Healthcare latest pipeline guide Ovarian Cancer - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Ovarian Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ovarian Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ovarian Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 2, 14, 141, 144, 7, 221, 26 and 10 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 10, 12, 45 and 8 molecules, respectively.

Ovarian Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Ovarian Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Ovarian Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Ovarian Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Ovarian Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Ovarian Cancer (Oncology)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Ovarian Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Ovarian Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 3-V Biosciences Inc
  • Bionomics Ltd
  • F. Hoffmann-La Roche Ltd
  • Kyowa Hakko Kirin Co Ltd
  • Oncobiologics Inc
  • Sanofi Pasteur SA
  • MORE
Introduction

Ovarian Cancer - Overview

Ovarian Cancer - Therapeutics Development

Ovarian Cancer - Therapeutics Assessment

Ovarian Cancer - Companies Involved in Therapeutics Development

Ovarian Cancer - Drug Profiles

Ovarian Cancer - Dormant Projects

Ovarian Cancer - Discontinued Products

Ovarian Cancer - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Ovarian Cancer, H2

Number of Products under Development by Companies, H2

Number of Products under Development by Universities/Institutes, H2

Products under Development by Companies, H2

Products under Development by Universities/Institutes, H2

Number of Products by Stage and Target, H2

Number of Products by Stage and Mechanism of Action, H2

Number of Products by Stage and Route of Administration, H2

Number of Products by Stage and Molecule Type, H2

Ovarian Cancer - Pipeline by 3-V Biosciences Inc, H2

Ovarian Cancer - Pipeline by 4SC AG, H2

Ovarian Cancer - Pipeline by AB Science SA, H2

Ovarian Cancer - Pipeline by AbbVie Inc, H2

Ovarian Cancer - Pipeline by AbGenomics International Inc, H2

Ovarian Cancer - Pipeline by Adaptimmune Therapeutics Plc, H2

Ovarian Cancer - Pipeline by Adgero Biopharmaceuticals Holdings Inc, H2

Ovarian Cancer - Pipeline by Advanced Cancer Therapeutics LLC, H2

Ovarian Cancer - Pipeline by Advantagene Inc, H2

Ovarian Cancer - Pipeline by Advenchen Laboratories LLC, H2

Ovarian Cancer - Pipeline by Aeterna Zentaris Inc, H2

Ovarian Cancer - Pipeline by Alethia Biotherapeutics Inc, H2

Ovarian Cancer - Pipeline by AlfaSigma SpA, H2

Ovarian Cancer - Pipeline by Alkermes Plc, H2

Ovarian Cancer - Pipeline by Allist Shanghai Pharmaceutical Technology Co Ltd, H2

Ovarian Cancer - Pipeline by Almac Discovery Ltd, H2

Ovarian Cancer - Pipeline by Alpha Cancer Technologies Inc, H2

Ovarian Cancer - Pipeline by Alteogen Inc, H2

Ovarian Cancer - Pipeline by Altor BioScience Corp, H2

Ovarian Cancer - Pipeline by Ambrx Inc, H2

Ovarian Cancer - Pipeline by Amgen Inc, H2

Ovarian Cancer - Pipeline by Amunix Operating Inc, H2

Ovarian Cancer - Pipeline by Anavex Life Sciences Corp, H2

Ovarian Cancer - Pipeline by ANP Technologies Inc, H2

Ovarian Cancer - Pipeline by AntiCancer Inc, H2

Ovarian Cancer - Pipeline by Antigen Express Inc, H2

Ovarian Cancer - Pipeline by Antoxis Ltd, H2

Ovarian Cancer - Pipeline by Aphios Corp, H2

Ovarian Cancer - Pipeline by Aposense Ltd, H2

Ovarian Cancer - Pipeline by Aprea AB, H2

Ovarian Cancer - Pipeline by arGEN-X BV, H2

Ovarian Cancer - Pipeline by ARMO Biosciences Inc, H2

Ovarian Cancer - Pipeline by Armour Therapeutics Inc, H2

Ovarian Cancer - Pipeline by ArQule Inc, H2

Ovarian Cancer - Pipeline by Array BioPharma Inc, H2

Ovarian Cancer - Pipeline by Arrien Pharmaceuticals LLC, H2

Ovarian Cancer - Pipeline by Astellas Pharma Inc, H2

Ovarian Cancer - Pipeline by Astex Pharmaceuticals Inc, H2

Ovarian Cancer - Pipeline by AstraZeneca Plc, H2

Ovarian Cancer - Pipeline by Atara Biotherapeutics Inc, H2

Ovarian Cancer - Pipeline by Athenex Inc, H2

Ovarian Cancer - Pipeline by AVEO Pharmaceuticals Inc, H2

Ovarian Cancer - Pipeline by Avipep Pty Ltd, H2

Ovarian Cancer - Pipeline by Basilea Pharmaceutica Ltd, H2

Ovarian Cancer - Pipeline by Bavarian Nordic A/S, H2

Ovarian Cancer - Pipeline by Bayer AG, H2

Ovarian Cancer - Pipeline by BeiGene Ltd, H2

Ovarian Cancer - Pipeline by Bio-Path Holdings Inc, H2

Ovarian Cancer - Pipeline by BioCancell Ltd, H2

Ovarian Cancer - Pipeline by BioMoti Ltd, H2

Ovarian Cancer - Pipeline by Bionomics Ltd, H2

Ovarian Cancer - Pipeline by BioNTech AG, H2

Ovarian Cancer - Pipeline by Biscayne Pharmaceuticals Inc, H2

Ovarian Cancer - Pipeline by Boehringer Ingelheim GmbH, H2

Ovarian Cancer - Pipeline by Boston Biomedical Inc, H2

Ovarian Cancer - Pipeline by Bristol-Myers Squibb Co, H2

Ovarian Cancer - Pipeline by Caladrius Biosciences Inc, H2

Ovarian Cancer - Pipeline by Calithera Biosciences Inc, H2

Ovarian Cancer - Pipeline by CASI Pharmaceuticals Inc, H2

Ovarian Cancer - Pipeline by Cavion LLC, H2

Ovarian Cancer - Pipeline by CBT Pharmaceuticals Inc, H2

Ovarian Cancer - Pipeline by Celgene Corp, H2

Ovarian Cancer - Pipeline by Celldex Therapeutics Inc, H2

Ovarian Cancer - Pipeline by Celleron Therapeutics Ltd, H2

Ovarian Cancer - Pipeline by Cellular Biomedicine Group Inc, H2

List of Figures

Number of Products under Development for Ovarian Cancer, H2

Number of Products under Development by Companies, H2

Number of Products under Development by Universities/Institutes, H2

Number of Products by Top 10 Targets, H2

Number of Products by Stage and Top 10 Targets, H2

Number of Products by Top 10 Mechanism of Actions, H2

Number of Products by Stage and Top 10 Mechanism of Actions, H2

Number of Products by Routes of Administration, H2

Number of Products by Stage and Routes of Administration, H2

Number of Products by Top 10 Molecule Types, H2

Number of Products by Stage and Top 10 Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • 3-V Biosciences Inc
  • 4SC AG
  • AB Science SA
  • AbbVie Inc
  • AbGenomics International Inc
  • Adaptimmune Therapeutics Plc
  • Adgero Biopharmaceuticals Holdings Inc
  • Advanced Cancer Therapeutics LLC
  • Advantagene Inc
  • Advenchen Laboratories LLC
  • Aeterna Zentaris Inc
  • Alethia Biotherapeutics Inc
  • AlfaSigma SpA
  • Alkermes Plc
  • Allist Shanghai Pharmaceutical Technology Co Ltd
  • Almac Discovery Ltd
  • Alpha Cancer Technologies Inc
  • Alteogen Inc
  • Altor BioScience Corp
  • Ambrx Inc
  • Amgen Inc
  • Amunix Operating Inc
  • Anavex Life Sciences Corp
  • ANP Technologies Inc
  • AntiCancer Inc
  • Antigen Express Inc
  • Antoxis Ltd
  • Aphios Corp
  • Aposense Ltd
  • Aprea AB
  • arGEN-X BV
  • ARMO Biosciences Inc
  • Armour Therapeutics Inc
  • ArQule Inc
  • Array BioPharma Inc
  • Arrien Pharmaceuticals LLC
  • Astellas Pharma Inc
  • Astex Pharmaceuticals Inc
  • AstraZeneca Plc
  • Atara Biotherapeutics Inc
  • Athenex Inc
  • AVEO Pharmaceuticals Inc
  • Avipep Pty Ltd
  • Basilea Pharmaceutica Ltd
  • Bavarian Nordic A/S
  • Bayer AG
  • BeiGene Ltd
  • Bio-Path Holdings Inc
  • BioCancell Ltd
  • BioMoti Ltd
  • Bionomics Ltd
  • BioNTech AG
  • Biscayne Pharmaceuticals Inc
  • Boehringer Ingelheim GmbH
  • Boston Biomedical Inc
  • Bristol-Myers Squibb Co
  • Caladrius Biosciences Inc
  • Calithera Biosciences Inc
  • CASI Pharmaceuticals Inc
  • Cavion LLC
  • CBT Pharmaceuticals Inc
  • Celgene Corp
  • Celldex Therapeutics Inc
  • Celleron Therapeutics Ltd
  • Cellular Biomedicine Group Inc
  • Celon Pharma SA
  • Celprogen Inc
  • Celsion Corp
  • Celyad SA
  • Ceronco Biosciences
  • CerRx Inc
  • Chipscreen Biosciences Ltd
  • Cielo Therapeutics Inc
  • Clovis Oncology Inc
  • CohBar Inc
  • Coherus BioSciences Inc
  • Commence Bio Inc
  • Compliment Corp
  • Corcept Therapeutics Inc
  • Critical Outcome Technologies Inc
  • Cyclacel Pharmaceuticals Inc
  • CytomX Therapeutics Inc
  • Cytori Therapeutics Inc
  • CZ BioMed Corp
  • DAE HWA Pharmaceutical Co Ltd
  • Deciphera Pharmaceuticals LLC
  • DEKK-TEC Inc
  • DelMar Pharmaceuticals Inc
  • Dr. Reddy's Laboratories Ltd
  • Ecrins Therapeutics SAS
  • Eisai Co Ltd
  • Eli Lilly and Co
  • Endocyte Inc
  • EntreChem SL
  • Epigen Biosciences Inc
  • EpiThany Inc
  • Epizyme Inc
  • Esperance Pharmaceuticals Inc
  • Exelixis Inc
  • F. Hoffmann-La Roche Ltd
  • Faron Pharmaceuticals Oy
  • Fate Therapeutics Inc
  • Forty Seven Inc
  • Fujifilm Holdings Corporation
  • Galena Biopharma Inc
  • GamaMabs Pharma SA
  • Gene Techno Science Co Ltd
  • Genelux Corp
  • Genentech Inc
  • Genisphere LLC
  • Genmab A/S
  • Genor BioPharma Co Ltd
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • Glenmark Pharmaceuticals Ltd
  • GlycoNex Inc
  • Glycotope GmbH
  • GP Pharm SA
  • Gradalis Inc
  • GW Pharmaceuticals Plc
  • Halozyme Therapeutics Inc
  • Hanmi Pharmaceuticals Co Ltd
  • Hemispherx Biopharma Inc
  • Horizon Pharma Plc
  • Ideaya Biosciences Inc
  • Ignyta Inc
  • Ildong Pharmaceutical Co Ltd
  • IMMD Inc
  • Immix BioPharma Inc
  • Immune Design Corp
  • Immune Pharmaceuticals Inc
  • Immunocore Ltd
  • ImmunoGen Inc
  • Immunomedics Inc
  • Immunovaccine Inc
  • IMPACT Therapeutics Inc
  • Imugene Ltd
  • Incyte Corp
  • Innate Pharma SA
  • Innovation Pharmaceuticals Inc
  • Inovio Pharmaceuticals Inc
  • Inventiva
  • Iovance Biotherapeutics Inc
  • ITUS Corp
  • Jiangsu Hengrui Medicine Co Ltd
  • Jiangsu Kanion Pharmaceutical Co Ltd
  • Johnson & Johnson
  • Juno Therapeutics Inc
  • Karyopharm Therapeutics Inc
  • Kazia Therapeutics Ltd
  • Kringle Pharma Inc
  • Kyowa Hakko Kirin Co Ltd
  • La Jolla Pharmaceutical Company
  • Laboratoire HRA Pharma SAS
  • Lantern Pharma Inc
  • LATITUDE Pharmaceuticals Inc
  • LegoChem Biosciences Inc
  • Lidds AB
  • Lixte Biotechnology Holdings Inc
  • Loxo Oncology Inc
  • Lycera Corp
  • Lymphocyte Activation Technologies SA
  • MabVax Therapeutics Holdings Inc
  • MacroGenics Inc
  • Madrigal Pharmaceuticals Inc.
  • Mateon Therapeutics Inc
  • MaxiVAX SA
  • Mebiopharm Co Ltd
  • MediaPharma SRL
  • MedImmune LLC
  • Medivir AB
  • Merck & Co Inc
  • Merck KGaA
  • Merrimack Pharmaceuticals Inc
  • Mersana Therapeutics Inc
  • Merus NV
  • Microlin Bio Inc
  • Millennium Pharmaceuticals Inc
  • Minerva Biotechnologies Corp
  • Moleculin Biotech Inc
  • MolMed SpA
  • Monopar Therapeutics LLC
  • Morphotek Inc
  • Mycenax Biotech Inc
  • NanoVector Inc
  • NantKwest Inc
  • Natco Pharma Ltd
  • NBE-Therapeutics AG
  • Nektar Therapeutics
  • Neovacs SA
  • Nerviano Medical Sciences Srl
  • Neurimmune Holding AG
  • NewLink Genetics Corp
  • Northwest Biotherapeutics Inc
  • Novartis AG
  • NovaTarg Therapeutics Inc
  • Noviga Research AB
  • Noxopharm Ltd
  • NuCana Plc
  • Oasmia Pharmaceutical AB
  • OBI Pharma Inc
  • Omeros Corp
  • Omnitura Therapeutics Inc
  • OncBioMune Pharmaceuticals Inc
  • Oncobiologics Inc
  • Oncodesign SA
  • Oncolix Inc
  • Oncolytics Biotech Inc
  • OncoMed Pharmaceuticals Inc
  • OncoResponse Inc
  • OncoTartis Inc
  • OncoTherapy Science Inc
  • Oncternal Therapeutics Inc
  • Ono Pharmaceutical Co Ltd
  • Opsona Therapeutics Ltd
  • Optimum Therapeutics LLC
  • ORCA Therapeutics BV
  • Oric Pharmaceuticals Inc
  • OSE Immunotherapeutics
  • Oxford BioMedica Plc
  • Pangaea Biotech SL
  • Patrys Ltd
  • PDS Biotechnology Corp
  • PEP-Therapy SAS
  • Pfizer Inc
  • Pharma Mar SA
  • PharmAust Ltd
  • Pharmicell Co Ltd
  • Plexxikon Inc
  • Polaris Pharmaceuticals Inc
  • Precision Biologics Inc
  • Propanc Biopharma Inc
  • Protheragen Inc
  • PsiOxus Therapeutics Ltd
  • PTC Therapeutics Inc
  • Puma Biotechnology Inc
  • Radius Health Inc
  • Recepta Biopharma SA
  • Rexahn Pharmaceuticals Inc
  • Rgenix Inc
  • Richter Gedeon Nyrt
  • Rigel Pharmaceuticals Inc
  • Rosetta Genomics Ltd
  • RS Research
  • Rubicon Biotechnology Inc
  • RXi Pharmaceuticals Corp
  • Samumed LLC
  • Sanofi
  • Sanofi Pasteur SA
  • SATT North SAS
  • Scancell Holdings Plc
  • Sellas Life Sciences Group Ltd
  • Senhwa Biosciences Inc
  • Sequoia Sciences Inc
  • Siamab Therapeutics Inc
  • Sierra Oncology Inc
  • Sigma-Tau SpA
  • Sillajen Biotherapeutics
  • Sitka Biopharma Inc
  • Soricimed Biopharma Inc
  • Sorrento Therapeutics Inc
  • Sotio AS
  • Starpharma Holdings Ltd
  • Sumitomo Dainippon Pharma Co Ltd
  • Sun Pharma Advanced Research Company Ltd
  • Supratek Pharma Inc
  • Susavion Biosciences Inc
  • Sutro Biopharma Inc
  • Syndax Pharmaceuticals Inc
  • Synthon Holdings BV
  • Syros Pharmaceuticals Inc
  • Tactiva Therapeutics LLC
  • Taiho Pharmaceutical Co Ltd
  • Takis Srl
  • TapImmune Inc
  • Targovax ASA
  • TC BioPharm Ltd
  • Tesaro Inc
  • The Female Health Company
  • TheraTarget Inc
  • Tocagen Inc
  • TRACON Pharmaceuticals Inc
  • Transgene SA
  • TVAX Biomedical Inc
  • Tyrogenex Inc
  • Unleash Immuno Oncolytics Inc
  • ValiRx Plc
  • Vascular Biogenics Ltd
  • Vectorite Biomedical Inc
  • Verastem Inc
  • VG Life Sciences Inc
  • ViiV Healthcare UK Ltd
  • ViraTherapeutics GmbH
  • Vyriad Inc
  • Zymeworks Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll